Vise Technologies Inc. Acquires 3,432 Shares of Moderna, Inc. $MRNA

Vise Technologies Inc. raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 63.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,879 shares of the company’s stock after acquiring an additional 3,432 shares during the quarter. Vise Technologies Inc.’s holdings in Moderna were worth $1,710,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in MRNA. Blue Fin Capital Inc. bought a new stake in shares of Moderna during the 3rd quarter valued at $432,000. MGO One Seven LLC grew its holdings in Moderna by 8.7% during the 3rd quarter. MGO One Seven LLC now owns 3,428 shares of the company’s stock valued at $660,000 after buying an additional 275 shares in the last quarter. Americana Partners LLC bought a new stake in shares of Moderna during the third quarter valued at about $1,482,000. VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in shares of Moderna by 3.8% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 65,750 shares of the company’s stock valued at $12,661,000 after buying an additional 2,400 shares during the period. Finally, Partners Wealth Management LLC purchased a new stake in shares of Moderna in the third quarter worth about $773,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 40,294 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the sale, the president directly owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. The trade was a 2.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This trade represents a 4.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is currently owned by corporate insiders.

Moderna Price Performance

NASDAQ MRNA traded up $12.73 during trading hours on Friday, reaching $254.19. 16,295,043 shares of the stock traded hands, compared to its average volume of 18,981,452. The stock has a 50 day simple moving average of $191.85 and a two-hundred day simple moving average of $91.51. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $267.50. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The company has a market cap of $101.48 billion, a price-to-earnings ratio of -31.81 and a beta of 1.16.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The company’s revenue for the quarter was up 29.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.51) EPS. On average, analysts predict that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of $1.31 billion, up 29.2% year over year, and earnings of $0.38 per share, far ahead of analysts’ expectations for a loss. Stronger overseas COVID-19 vaccine sales helped drive the results. Reuters report on revenue and demand
• Positive Sentiment: Management raised its 2026 revenue-growth forecast to 15%–25%, from a prior outlook of up to 10%. The company also said it plans to reduce research and development spending, supporting its near-term financial performance. CNBC outlook report
• Positive Sentiment: Health Canada authorized Moderna’s seasonal flu and flu-COVID combination vaccines for adults 50 and older, opening a potential new market for its mRNA products. CBC report on Canadian approvals
• Positive Sentiment: Investors are also watching prospects for Moderna’s cancer vaccine: CEO Stéphane Bancel said it could have potential beyond melanoma. That adds pipeline excitement, though future commercial value remains uncertain. Yahoo Finance report on cancer vaccine prospects
• Neutral Sentiment: Moderna and GSK settled a patent dispute involving Moderna’s COVID and RSV shots. The settlement removes a source of legal uncertainty, but the available report does not specify its financial terms. Reuters report on patent settlement
• Negative Sentiment: The sharp rally has heightened concerns that expectations for the cancer-vaccine pipeline may be running ahead of near-term revenue potential. Moderna’s longer-term prospects still depend on sustaining vaccine sales and turning pipeline advances into commercial products. Barron’s analysis of Moderna’s earnings and valuation

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Brookline Capital Markets restated a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Citigroup reissued a “sell” rating on shares of Moderna in a research note on Friday, October 23rd. JPMorgan Chase & Co. boosted their target price on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. Berenberg Bank upped their target price on Moderna from $45.00 to $100.00 and gave the stock a “hold” rating in a research note on Friday, September 11th. Finally, Bank of America boosted their price objective on Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Six investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and a consensus target price of $107.10.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.